

Arrivo Bio to Present Early Clinical Data on RABI-767 at the 2025 American Pancreatic Association Annual Meeting

Poster selected as a “Poster of Distinction,” highlighting safety, pharmacokinetics, and preliminary efficacy data in predicted severe acute pancreatitis

MORRISVILLE, N.C., November 12, 2025 – [Arrivo Bio](#) will present new clinical data on RABI-767, a pancreatic lipase inhibitor in development for predicted severe acute pancreatitis, at the 2025 American Pancreatic Association (APA) Annual Meeting, taking place November 12–15 in San Diego, California.

The poster, which has been named a “Poster of Distinction” by the APA Poster Committee, summarizes findings from a Phase 1 clinical study evaluating the safety and pharmacokinetics of RABI-767 in healthy adults. It also includes preliminary safety and efficacy data from participants enrolled to date in Arrivo’s ongoing Phase 2 study in patients with predicted severe acute pancreatitis (SAP).

Key takeaways from the poster include:

- In the Phase 1 study, RABI-767 was well-tolerated in healthy adults following percutaneous ultrasound-guided intraperitoneal injection.
- In the ongoing Phase 2 study, RABI-767 delivered by endoscopic-ultrasound-guided (EUS-guided) peri-pancreatic injection has been well-tolerated in participants with predicted SAP.
- No adverse safety signals have been observed.
- Early results suggest promising signs of efficacy in participants with predicted SAP enrolled to-date in the Phase 2 study.

Poster Title: Early Clinical Evaluation of RABI-767 as a Potential Treatment for Predicted Severe Acute Pancreatitis

Presenter: Timothy B. Gardner, M.D., M.S., Dartmouth Hitchcock Medical Center and RABI-767-201 Study Lead Investigator

Date/Time: Friday, November 14, 2025, from 12:30 to 2:30 pm PST

Location: Pavilion Room, Loews Coronado Bay Resort, Coronado, California

RABI-767 received Fast Track Designation from the FDA in July 2024.

For more about Arrivo Bio and RABI-767, visit www.arrivobio.com.

About Arrivo Bio

Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier

lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RAB1-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

Media Contact:

Alexis Feinberg

Vice President, ICR Healthcare

Alexis.feinberg@icrhealthcare.com